Companies in #KRAS-Driven Cancers
Found 2 companies operating in this sector.
Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors for oncology, with a particular focus on designing brain-penetrant, resistance-selective compounds. Its lead programs target ROS1 and ALK in non-small cell lung cancer, with additional programs in HER2 and KRAS. The company has positioned its chemistry platform to address the dual challenges of kinase resistance and CNS metastases, and in June 2026 signed a partnership with GSK giving GSK ex-US rights to two of its kinase inhibitors in a deal structured to take advantage of a post-ASCO share-price dip.
Silexion Therapeutics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi)-based cancer therapies and delivery systems for malignant solid tumors, built on its proprietary LODER delivery platform. Lead programs include SIL204, an RNAi therapeutic targeting KRAS-driven cancers now in clinical development, and SiG12D-LODER, which completed an open-label Phase 1 trial in pancreatic cancer; Prostate-LODER and GBM-LODER are in preclinical development. The company collaborates with Evonik on advanced siRNA formulation and is headquartered in Jerusalem, Israel, with a Nasdaq listing since 2025.